The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD. A rare case of diffuse large B-cell lymphoma (DLBCL) accompanied by ...

The instruments that were the most comprehensive and considered all 4 components [of resilience] were the 25-item CD-RISC, the Chinese version of the 25-item CD-RISC, and the Bharathiar University ...

The median progression-free survival was 10.7 months, and the median intracranial progression-free survival was 16.1 months. The combination of brain radiotherapy and chemoimmunotherapy could be a ...

Improved survival seen with perioperative chemotherapy with FLOT versus preoperative chemoradiotherapy. HealthDay News — For patients with resectable esophageal adenocarcinoma, perioperative ...